Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.

Article Details

Citation

Adjei AA

Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.

Lung Cancer. 2001 Dec;34 Suppl 4:S103-5.

PubMed ID
11742712 [View in PubMed
]
Abstract

Pemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers. Gemcitabine is a broadly active pyrimidine nucleoside antimetabolite, which is approved for the treatment of pancreatic and non-small cell lung cancers. Three preclinical studies have been reported that show cytotoxic synergy between gemcitabine and pemetrexed. Clinical activity with this combination has been observed in a phase I study, with partial responses in three of five patients previously treated for non-small cell lung cancer. An international phase II study of this combination in non-small cell lung cancer is ongoing.

DrugBank Data that Cites this Article

Drug Targets
Drug Target Kind Organism Ph值armacological Action Actions
Pemetrexed Dihydrofolate reductase Protein Humans
Yes
Inhibitor
Details
Pemetrexed Thymidylate synthase Protein Humans
Yes
Inhibitor
Details
Pemetrexed Trifunctional purine biosynthetic protein adenosine-3 Protein Humans
Yes
Inhibitor
Details